Overview
Portfolio
More
All Kochi Alliance Capital
Tokyo, Japan
All Kochi Alliance Capital (AKAC) invests in early‑stage university‑spun out ventures originating from Kochi Prefecture, aiming to commercialise research outcomes and create new industries for regional economic revitalis...
Portfolio
3+
Employees
1000+
Founded
N/A
AUM
≈ $201.0M
Investment focus
Stages
Seed
Industries
BiotechnologyClean Technology
Geographic scope
Japan
Fund details
Funds
高知県発ベンチャー投資事業有限責任組合
Vintage 2022 • $201.0M
Sources
All Kochi Alliance Capital
All Kochi Alliance Capital (AKAC) invests in early‑stage university‑spun out ventures originating from Kochi Prefecture, aiming to commercialise research outcomes and create new industries for regional economic revitalisation. The firm provides capital, hands‑on support and leverages local partnerships to nurture biotech, cleantech and other innovative sectors rooted in academic research.
Portfolio
3+
Employees
1000+
Founded
N/A
AUM
≈ $201.0M
Funds
高知県発ベンチャー投資事業有限責任組合 · Vintage 2022 • $201.0M
Stages
Seed
Industries
BiotechnologyClean Technology
Geographic scope
Japan
Sources
Showing 3 of 3 matched portfolio companies
Farm is a platform that facilitates investment in agricultural land through a digital marketplace, connecting investors with landowners. This approach addresses the challenge of limited access to farmland investment opportunities, enabling users to diversify their portfolios and participate in the agricultural sector.
Provides a privacy-preserving analytics and AI platform that enables data scientists and analysts to query sensitive data without direct access, using differential privacy, synthetic data generation, and privacy-first query rewriting. This approach ensures compliance with data protection regulations, prevents breaches, and allows organizations to unlock the full value of their data while maintaining security and privacy.
Funding: $2.7M
Rough estimate of the amount of funding raised
Funding: $2.7M
Rough estimate of the amount of funding raised
Physios Biotech develops microphysiological systems (MPS) that replicate human organ functions and rare disease environments, utilizing advanced nanotechnology for high human extrapolation. Their technology reduces reliance on animal testing and accelerates drug development timelines by providing accurate safety evaluations and therapeutic assessments for rare cancers.